Is Nurix Therapeutics, Inc. (NRIX) a Buy, Sell, or Hold?
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$22.98 USD
$0.27 (1.19%)
- Volume
- 1.57M
- Average Volume
- 1.97M
- Market Capitalization
- $1.99B
- P/E Ratio
- -6.66
- Dividend Yield
- 0.00%
- Price Target
- $34.00
- Year High
- $25.09
- Year Low
- $8.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.34
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Arthur T. Sands |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NRIX |
| CUSIP | 67080M103 |
| CIK | 0001549595 |
| Web | https://www.nurixtx.com |
| Phone | 415 660 5320 |
| Currency | USD |
| Employees | 317 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.14 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.34 |
| Quick Ratio | 6.34 |
| Cash Ratio | 0.94 |
Sales & Book Value
| Annual Sales | $83.98M |
| Price / Sales | 54.17 |
| Cash Flow | -2.74 |
| Price / Cash Flow | -6.54 |
| Price / Book | 6.34 |
Price Target and Rating
| Average Stock Price Forecast | $34.00 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $23.00 |
| Forecast Upside/Downside | -32.41% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.05 |
| Trailing P/E Ratio | -6.66 |
| PEG Ratio | 0.25 |
| P/E Growth | 0.25 |
| Net Income | $-264.46M |
| Net Margin | -928.44% |
| Pretax Margin | -929.18% |
| Return on Equity | -76.09% |
| Return on Assets | -63.74% |
Financials Score
| AltmanZ Score | 4.73 |
| Piotroski Score | 2.00 |
| Working Capital | 384.46M |
| Total Assets | 535.54M |
| Ebit | -341.62M |
| Market Cap | 1.99B |
| Total Liabilities | 132.91M |
Poll Results
About Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It i ... s also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
2026-07-09 18:26:04
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $0.52 per share a year ago.
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-09 16:01:00
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
2026-07-01 11:01:05
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
2026-07-01 10:55:14
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nurix Stock Up 29% in a Month: Here's What You Should Know
2026-06-26 12:05:36
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
2026-06-26 11:45:32
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nurix Therapeutics Deal With Roche Is Worth Betting On
2026-06-11 09:48:54
Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validate NRIX's bexobrutideg and its potential as a broader platform in the long term. NRIX's bexobrutideg is easily their main value driver, and after NRIX's recent equity raises and deal with Roche, it looks like they should have enough runway for the foreseeable future.
2026-06-11 07:00:00
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced updated clinical data from the Company's ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL).
Frequently Asked Questions
-
What is the current Nurix Therapeutics, Inc. (NRIX) stock price?
-
Nurix Therapeutics, Inc.(NASDAQ:NRIX) stock price is $22.98 in the last trading session. During the trading session, NRIX stock reached the peak price of $25.085 while $8.195 was the lowest point it dropped to. The percentage change in NRIX stock occurred in the recent session was 1.19% while the dollar amount for the price change in NRIX stock was $0.27.
-
NRIX's industry and sector of operation?
-
The NASDAQ listed NRIX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NRIX?
-
Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer
Gwenn Hansen | Chief Scientific Officer
Jason Kantor | Chief Business Officer
John Kuriyan | Founder & Member of Scientific Advisory Board
Christopher Phelps | Senior Vice President & Head of Early Drug Discovery -
How many employees does NRIX have?
-
Number of NRIX employees currently stands at 317. NRIX operates from 1600 Sierra Point Parkway, Brisbane, CA 94005, US.
-
Link for NRIX official website?
-
Official Website of NRIX is: https://www.nurixtx.com
-
How do I contact NRIX?
-
NRIX could be contacted at phone #415 660 5320 and can also be accessed through its website. NRIX operates from 1600 Sierra Point Parkway, Brisbane, CA 94005, US.
-
How many shares of NRIX are traded daily?
-
The average number of NRIX shares traded daily for last 3 months was 1.97M.
-
What is the market cap of NRIX currently?
-
The market value of NRIX currently stands at $1.99B with its latest stock price at $22.98